Resminostat hydrochloride is primarily used in the field of oncology as a histone deacetylase (HDAC) inhibitor. It is being investigated for its potential to treat various types of cancers, including hepatocellular carcinoma (HCC) and cutaneous T-cell lymphoma (CTCL). By inhibiting HDAC enzymes, it helps in the regulation of gene expression, leading to the suppression of tumor growth and the induction of cancer cell death. Additionally, it is being explored for its role in combination therapies, where it may enhance the efficacy of other anticancer drugs. Its application in clinical trials aims to provide new therapeutic options for patients with resistant or advanced cancers.